Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tremelimumba

- PMLiVE

MedImmune partners with university on protein formulation science

Four-year partnership to research antibodies and novel proteins

- PMLiVE

NICE consults on reducing melanoma cases

New guidance set to focus on diagnosing and managing the skin cancer  

- PMLiVE

AZ files gout drug lesinurad in Europe

Acquired drug as part of its takeover of Ardea Biosciences in 2012

- PMLiVE

MedImmune partners with US National Cancer Institute

Will research immunotherapies, imaging and stem cell treatments

- PMLiVE

AZ’s Brilinta clears cardiovascular outcomes trial

Found to reduce chance of recurring cardiovascular events

- PMLiVE

Immunocore names CEO

Eliot Forster is chairman of the MedCity project

- PMLiVE

AZ’s Lynparza cleared for ovarian cancer in Europe

Comes three years after company ditched drug due to poor trial results

- PMLiVE

Roche and Exelixis file melanoma duo in US

Combination of cobimetinib and Zelboraf improved progression-free survival by 9.9 months

- PMLiVE

AZ’s constipation drug Moventig cleared in EU

Claims to be the first PAMORA to be approved in the EU

- PMLiVE

AZ and Lilly start BACE inhibitor trial in Alzheimer’s

Early trials show promise for the BACE inhibitor AZD3293

- PMLiVE

AZ’s new COPD therapy gets green light in Europe

EC backs Duaklir in chronic respiratory condition

- PMLiVE

AZ says cancer will be ‘sixth growth platform’

Firm currently has 14 drugs in phase III trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links